Controversy surrounding the Sputnik V vaccine

[1]  M. Lipsitch,et al.  Covid-19 Breakthrough Infections in Vaccinated Health Care Workers , 2021, The New England journal of medicine.

[2]  M. Beranek,et al.  Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort , 2021, Vaccine.

[3]  J. Kamil,et al.  Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants , 2021, Nature Communications.

[4]  R. Myers,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.

[5]  J. Mayerle,et al.  Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein , 2021, Blood.

[6]  V. Gushchin,et al.  An Open, Non-Randomised, 1/2 Phase Study on the Safety, Tolerability, and Immunogenicity of Single Dose 'Sputnik Light' Vaccine for Prevention of Coronavirus Infection in Healthy Adults , 2021, SSRN Electronic Journal.

[7]  A. Sommet,et al.  Efficacy of COVID‐19 vaccines: Several modes of expression should be presented in scientific publications , 2021, Fundamental & clinical pharmacology.

[8]  Corina I. García,et al.  Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose , 2021, Cell Reports Medicine.

[9]  D. Gori,et al.  ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance , 2021, EClinicalMedicine.

[10]  B. Nogrady.  Mounting evidence suggests Sputnik COVID vaccine is safe and effective , 2021, Nature.

[11]  A. Shchetinin,et al.  Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants , 2021, Vaccines.

[12]  P. Choi.  Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. , 2021, The New England journal of medicine.

[13]  J. Zahradník,et al.  SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity , 2021, Cell Host & Microbe.

[14]  S. Hasnain,et al.  SARS-CoV-2 variants of concern are emerging in India , 2021, Nature Medicine.

[15]  L. Klimek,et al.  COVID-19-Impfungen: Replizierend oder Nichtreplizierend? , 2021, Laryngo-Rhino-Otologie.

[16]  T. Caspari,et al.  The Spike of Concern—The Novel Variants of SARS-CoV-2 , 2021, Viruses.

[17]  N. Javed,et al.  COVID-19 Vaccination in Developing Nations: Challenges and Opportunities for Innovation , 2021, Infectious disease reports.

[18]  J. Berkhof,et al.  Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial , 2021, The Lancet.

[19]  D. Logunov,et al.  Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial – Authors' reply , 2021, The Lancet.

[20]  Rajesh Venkatraman,et al.  Covid-19 Vaccine Authorized in India-A Mini Review , 2021 .

[21]  Christoffer van Tulleken.  Covid-19: Sputnik vaccine rockets, thanks to Lancet boost , 2021, BMJ.

[22]  G. Lawton.  Sputnik V vaccine goes global , 2021, New Scientist.

[23]  Andreas Greinacher,et al.  Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination , 2021, The New England journal of medicine.

[24]  B. Luan,et al.  Insights into SARS-CoV-2’s Mutations for Evading Human Antibodies: Sacrifice and Survival , 2021, Journal of medicinal chemistry.

[25]  Jialu Zhang,et al.  Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies , 2021, Expert review of vaccines.

[26]  J. Kamil,et al.  Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants , 2021, medRxiv.

[27]  L. Calzetta,et al.  Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials , 2021, Vaccines.

[28]  D. Stuart,et al.  Antibody evasion by the P.1 strain of SARS-CoV-2 , 2021, Cell.

[29]  M. Cazzola,et al.  Disputes over the production and dissemination of misinformation in the time of COVID-19 , 2021, Respiratory Medicine.

[30]  Chris Baraniuk.  Covid-19: What do we know about Sputnik V and other Russian vaccines? , 2021, BMJ.

[31]  A. Carfi,et al.  Novel approaches for vaccine development , 2021, Cell.

[32]  E. M. Choi.  COVID-19 vaccines for low- and middle-income countries , 2021, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[33]  E. James.  Disrupting vaccine logistics , 2021, International health.

[34]  Vineet D. Menachery,et al.  The N501Y spike substitution enhances SARS-CoV-2 transmission , 2021, bioRxiv.

[35]  John P. Moore.  Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy. , 2021, JAMA.

[36]  M. Cazzola,et al.  SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines , 2021, Vaccines.

[37]  Christopher M. Snyder,et al.  Market design to accelerate COVID-19 vaccine supply , 2021, Science.

[38]  M. Hernán,et al.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting , 2021, The New England journal of medicine.

[39]  D. Stuart,et al.  Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera , 2021, Cell.

[40]  P. Khavari,et al.  SARS-CoV-2 B.1.1.7 and B.1.351 Spike variants bind human ACE2 with increased affinity , 2021, bioRxiv.

[41]  D. Stuart,et al.  Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera , 2021, Cell.

[42]  Stephanie S. Chen,et al.  Emergence of a Novel SARS-CoV-2 Variant in Southern California. , 2021, JAMA.

[43]  B. Autran,et al.  SARS-CoV-2 variants and ending the COVID-19 pandemic , 2021, The Lancet.

[44]  S. Figar,et al.  ACTIVE SURVEILLANCE OF THE SPUTNIK V VACCINE IN HEALTH WORKERS , 2021, medRxiv.

[45]  V. Gushchin,et al.  Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia , 2021, The Lancet.

[46]  Ebenezer Tumban.  Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval , 2020, Viruses.

[47]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[48]  S. Buchbinder,et al.  Use of adenovirus type-5 vectored vaccines: a cautionary tale , 2020, The Lancet.

[49]  D. Logunov,et al.  Safety and efficacy of the Russian COVID-19 vaccine: more information needed – Authors’ reply , 2020, The Lancet.

[50]  Piero Carninci,et al.  Safety and efficacy of the Russian COVID-19 vaccine: more information needed , 2020, The Lancet.

[51]  A. Gintsburg,et al.  Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia , 2020, The Lancet.

[52]  M. Cazzola,et al.  Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review , 2020, Respiratory Medicine.

[53]  Y. Hu,et al.  Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial , 2020, The Lancet.

[54]  K. Mansfield,et al.  International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. , 2011, Vaccine.

[55]  G. Pantaleo,et al.  Activation of a dendritic cell–T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells , 2008, The Journal of experimental medicine.

[56]  Ping Li,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020 .

[57]  S. Moutinho.  Is Russia’s COVID-19 vaccine safe? Brazil’s veto of Sputnik V sparks lawsuit threat and confusion , 2022, Science.